Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
141. |
ECCT/20/11/05 | HOPE Kids 2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2) |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. KEMRI/CRDR Clinical Research Annex (Nairobi City county) 3. Strathmore University Medical Centre (Nairobi City county) 4. KEMRI/CRDR Siaya (Siaya county) |
03-03-2021 |
View |
142. |
ECCT/23/10/06 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Godfrey Allan Otieno 2. Dr Videlis Nduba Site(s) in Kenya 1. KEMRI-Kondele Children’s Hospital (Kisumu county) 2. KEMRI CRDR Clinical Research Annex (Nairobi City county) |
19-12-2023 |
View |
143. |
ECCT/23/12/03 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Benson Ochieng Singa Site(s) in Kenya 1. Migori County Referral Hospital (Migori county) |
07-05-2024 |
View |
144. |
ECCT/26/04/01 | ACRN-MNK02-301 A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG ®) versus placebo on weight gain in underweight infants. |
Principal Investigator(s) 1. Prof. Videlis Nduba Site(s) in Kenya 1. KEMRI-CRDR (Nairobi City county) 2. KEMRI-MTWAPA (Kilifi county) 3. Moi University Clinical Research Centre (Uasin Gishu county) |
21-10-2026 |
View |
145. |
ECCT/25/11/04 | Bifin02 and LGG® A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. Moi University Clinical Research (Uasin Gishu county) 2. Kenya Medical Research Institute (KEMRI) CRDR Off Raila Odinga, Nairobi Kenya (Nairobi City county) 3. Kenya Medical Research Institute (KEMRI) Mwtapa (Kilifi county) |
19-08-2026 |
View |
146. |
ECCT/25/11/01 | COMBO-CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr. Wilson Muraya Site(s) in Kenya 1. KENYA MEDICAL RESEARCH INSTITUTE- MTWAPA (Kilifi county) 2. Moi University Clinical Research Centre-MUCRU (Uasin Gishu county) 3. Kenya Medical Research Institute (KEMRI) CRDR (Nairobi City county) |
21-06-2026 |
View |
147. |
ECCT/26/03/01 | C1091009 Study A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute Kisumu County Referral Hospital (Kisumu county) 2. KEMRI Butere Clinical Research Centre (Kakamega county) 3. Kenya Medical Research Institute Walter Reed Project (Kericho county) 4. Kenya Medical Research Institute (KEMRI) - Centre for Global Health Research (Kisumu county) |
26-08-2026 |
View |
148. |
ECCT/15/06/03 | DolutegrAvir With NRTIs as second-line treatment (DAWNING) A Phase 3b, randomised, open-label study of the antiviral activity and safety of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy |
Principal Investigator(s) 1. Dr. Evans Inyangala Amukoye 2. Dr. Maricianah Atieno Onono Site(s) in Kenya 1. Center for Respiratory Diseases Research, CRDR, KEMRI, Nairobi (Nairobi City county) 2. KEMRI-Research Care and Training Program (RCTP), Family AIDS Care and Education Services (FACES), Lumumba health centre (Kisumu county) |
29-07-2015 |
View |
149. |
ECCT/21/07/05 | CARES A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine from Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults in Sub-Saharan Africa |
Principal Investigator(s) 1. Dr Reena Shah Site(s) in Kenya 1. Aga Khan University Hospital Nairobi (Nairobi City county) 2. KEMRI Walter Reed Project (Kericho county) 3. Moi University Clinical Research Centre (Uasin Gishu county) |
09-11-2021 |
View |
150. |
ECCT/23/02/06 | BOHEMIA Safety and Efficacy A Phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in Kwale, Kenya. |
Principal Investigator(s) 1. Marta Ferreira Maia 2. Joseph Mwangangi Site(s) in Kenya Kwale county, subcounties Lungalunga and Msambweni |
25-06-2023 |
View |